X4 Pharmaceuticals rises as US FDA approves immunodeficiency therapy

X4 Pharmaceuticals

29/04/2024 12:09

** Drug developer X4 Pharmaceuticals'  XFOR.O  shares rise
9.9% to $1.29 premarket 
    ** U.S. FDA approves co's therapy to treat WHIM syndrome, a
rare genetic immunodeficiency disease, for use in patients aged
12 years or older 
    ** The therapy, which will be sold under brand name
Xolremdi, is first of its kind to get U.S. approval specifically
for WHIM syndrome's treatment
    ** WHIM is characterized by disorders in which body's immune
system does not function properly
    ** The approval is based on late-stage study where the
therapy showed 60% reduction in infection rate compared with
placebo 
    ** Up to last close, stock up 38.9% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))